Advertisements

U.S. FDA declines to approve Blueprint"s therapy for type of stomach cancer

U.S. FDA declines to approve Blueprint"s therapy for type of stomach cancer.....»»

Category: global-financeSource: reutersMay 15th, 2020

FDA declines to approve Daiichi Sankyo"s blood cancer treatment

FDA declines to approve Daiichi Sankyo"s blood cancer treatment.....»»

Category: global-financeSource: reutersJun 21st, 2019

Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia

Biocon#39;s partner Mylan launches first biosimilar of trastuzumab in Australia.....»»

Category: topSource: moneycontrolAug 1st, 2019

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy.....»»

Category: global-financeSource: reutersJan 13th, 2018

Novartis gene therapy approval signals new cancer treatment era

Novartis gene therapy approval signals new cancer treatment era.....»»

Category: global-financeSource: reutersAug 30th, 2017

Novartis approval for gene therapy signals new cancer treatment era

Novartis approval for gene therapy signals new cancer treatment era.....»»

Category: global-financeSource: reutersAug 30th, 2017

U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma

U.S. FDA declines to review Bristol Myers, bluebird therapy for multiple myeloma.....»»

Category: global-financeSource: reutersMay 13th, 2020

Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India

Zydus Cadila launches generic prostate cancer drug at nearly 70% less price in India.....»»

Category: topSource: moneycontrolMay 8th, 2020

U.S. FDA extends review of Bristol Myers" cancer therapy acquired in Celgene deal

U.S. FDA extends review of Bristol Myers" cancer therapy acquired in Celgene deal.....»»

Category: global-financeSource: reutersMay 6th, 2020

Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty

Merck profit rises, cuts 2020 forecast over COVID-19 uncertainty.....»»

Category: global-financeSource: reutersApr 28th, 2020

"Waiting game" for Oregon patient needing cancer surgery amid coronavirus

"Waiting game" for Oregon patient needing cancer surgery amid coronavirus.....»»

Category: global-financeSource: reutersApr 17th, 2020

AstraZeneca"s Imfinzi gets FDA nod to target small-cell lung cancer

AstraZeneca"s Imfinzi gets FDA nod to target small-cell lung cancer.....»»

Category: global-financeSource: reutersMar 30th, 2020

GIOSTAR Launches Stem Cell / Cancer Research and Therapy Center in Chandigarh, India

GIOSTAR Launches Stem Cell / Cancer Research and Therapy Center in Chandigarh, India.....»»

Category: press-releasesSource: prnewswireFeb 6th, 2020

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA

Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA.....»»

Category: topSource: moneycontrolDec 2nd, 2019

Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck

Novartis"s $90 million Swiss factory to help solve cell therapy bottleneck.....»»

Category: global-financeSource: reutersNov 28th, 2019

Immunotherapy Emerging as a Treatment of Hope for Those With Lung Cancer

Immunotherapy Emerging as a Treatment of Hope for Those With Lung Cancer.....»»

Category: press-releasesSource: prnewswireNov 20th, 2019

Housing Absorption Declines 13% in Q2 2019, New Launches Down 2% - ANAROCK

Housing Absorption Declines 13% in Q2 2019, New Launches Down 2% - ANAROCK.....»»

Category: press-releasesSource: prnewswireJul 9th, 2019

FDA declines to approve Acer Therapeutics" treatment for rare genetic disorder

FDA declines to approve Acer Therapeutics" treatment for rare genetic disorder.....»»

Category: global-financeSource: reutersJun 25th, 2019

AstraZeneca"s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

AstraZeneca"s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment.....»»

Category: global-financeSource: reutersJun 18th, 2019

Over 1.5 crore people will need chemotherapy globally each year by 2040: Study

Over 1.5 crore people will need chemotherapy globally each year by 2040: Study.....»»

Category: topSource: moneycontrolMay 13th, 2019

Novartis confident of Zolgensma supply, calls $2 million price "speculation"

Novartis confident of Zolgensma supply, calls $2 million price "speculation".....»»

Category: global-financeSource: reutersMay 8th, 2019